MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
The upset continued this month as Siemens (NYSE:SI) retained its seat at the top of the pyramid, although some of the clamor has died down regarding the company’s internal drama and earnings shortfalls.
Medtronic (NYSE:MDT) is still in 2nd place with a raft of stories about missing patient records, a $200 million acquisition outside its usual scope, legal updates and much more.
Covidien (NYSE:COV) rejoined the list at 3rd place, making headlines with positive earnings, a syringe recall and some news from emerging markets. Boston Scientific (NYSE:BSX) remains ever in 4th place, this month generating a swatch of financial news as well as legal and R&D updates.
Johnson & Johnson (NYSE:JNJ) slipped from 3rd to 5th place, although it was the focus of a prominent hacker’s 2013 Black Hat conference presentation as well as the focus of a number of regulatory hiccups and courtroom battles.

Siemens
- Siemens Healthcare’s Q2 profits soar on 3% sales growth
- New Siemens CEO: ‘Company is most definitely not in a crisis’

Medtronic
- Medtronic warns more than 2,700 patients on missing records
- Medtronic rolls out MRI-safe spinal stimulator for chronic pain
- Medtronic’s new implant delivers therapy and monitors brain activity at the same time
- Conflicting decisions and new tactics in Medtronic Infuse lawsuits
- Medtronic drops $200M on Cardiocom
- GPOs: Medtronic, St. Jude, Boston Scientific land new deals from Premier
- Medtronic files for FDA approval of drug-eluting balloon
- U.S. leans in Medtronic’s favor in Supreme Court case against Boston Scientific
- Medtronic dips on missed Q1 revenues
- German ban on Medtronic TAVI begins today, Edwards makes room for ‘compassionate cases’
- Another lawsuit against Medtronic’s Infuse proceeds in Arizona
- Medtronic hands Pioneer Plus catheters to Volcano in closed-doors deal
- Medtronic’s maneuvers may signal long-term struggles for industry
- Ishrak takes his work home: Medtronic opens 1st office in CEO’s birth land of Bangladesh

Covidien
- Covidien gains on Q3 earnings beat
- Boston Scientific, Covidien get in on SetPoint Medical’s $27M round
- CAS Medical wins a legal round against Covidien’s Nellcor
- Jury hands Covidien’s ev3 subsidiary a possible $275M loss
- Covidien recalls flush syringes
- South Korea is a "key market" in Covidien’s global strategy

Boston Scientific
- Labeling glitch with Boston Scientific’s Promus Element Plus prompts recall in Australia
- Boston Scientific, Covidien get in on SetPoint Medical’s $27M round
- Boston Scientific battles whistleblowers in spinal stimulation lawsuit
- Boston Scientific prices $1B debt offering
- GPOs: Medtronic, St. Jude, Boston Scientific land new deals from Premier
- Boston Scientific legal update: Guidant, Guidezilla and ongoing arguments
- U.S. leans in Medtronic’s favor in Supreme Court case against Boston Scientific
- Boston Scientific wraps up patient enrollment for Innova bare metal stent trial
- Boston Scientific lands FDA wins for cardiac ablation devices
- Boston Scientific’s new skin implant is less of a shock to the heart

Johnson & Johnson
- Hacking: Another year, another insulin pump maker outed on stage
- DePuy limb preservation system recall gets FDA’s highest-risk status
- China fines Johnson & Johnson in landmark price-fixing case
- Study: Abbott, Johnson & Johnson park billions in offshore tax havens
- Johnson & Johnson can exclude recall evidence in DePuy ASR bellwether lawsuit
- Medinol goes after J&J’s Cordis in stent patent war